BRIEF published on 06/18/2025 at 16:10, 1 year 4 months ago Eckert & Ziegler SE Declares EUR 0.50 Dividend at Annual General Meeting Annual General Meeting Shareholders Dividend Financial Year 2024 Eckert & Ziegler SE
PRESS RELEASE published on 06/18/2025 at 16:05, 1 year 4 months ago Annual General Meeting of Eckert & Ziegler SE Approves Dividend of EUR 0.50 Eckert & Ziegler SE's Annual General Meeting approves dividend of EUR 0.50 per share for 2024 fiscal year. Detailed voting results available online Annual General Meeting Shareholders Voting Results Dividend Eckert & Ziegler SE
BRIEF published on 06/05/2025 at 10:05, 1 year 5 months ago Eckert & Ziegler se développe avec l'approbation d'Illuccix® en Allemagne Gallium-68 Médecine Nucléaire Cancer De La Prostate Illuccix® Imagerie PSMA-PET
BRIEF published on 06/05/2025 at 10:05, 1 year 5 months ago Eckert & Ziegler Expands with Approval of Illuccix® in Germany Gallium-68 Nuclear Medicine Prostate Cancer Illuccix® PSMA-PET Imaging
PRESS RELEASE published on 06/05/2025 at 10:00, 1 year 5 months ago Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany Eckert & Ziegler announces the approval of Illuccix® PSMA-PET Imaging Agent in Germany, expanding its nuclear medicine portfolio and partnership with Telix Pharmaceuticals Eckert & Ziegler Germany Approval Illuccix PSMA-PET
BRIEF published on 05/30/2025 at 10:05, 1 year 5 months ago Eckert & Ziegler Hosts Successful Boston Radionuclide Theranostics Forum Precision Oncology Industry Collaboration Radiopharmaceuticals Theranostics Forum Event Insights
BRIEF published on 05/30/2025 at 10:05, 1 year 5 months ago Eckert & Ziegler organise avec succès le Boston Radionuclide Theranostics Forum Oncologie De Précision Produits Radiopharmaceutiques Collaboration Industrielle Forum Théranostique Informations Sur Les Événements
PRESS RELEASE published on 05/30/2025 at 10:00, 1 year 5 months ago Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, gathering key leaders to discuss radionuclides in precision oncology Innovation Eckert & Ziegler Precision Oncology Radiopharmaceuticals Boston Radionuclide Theranostics Forum
BRIEF published on 05/23/2025 at 10:05, 1 year 5 months ago Eckert & Ziegler reçoit à nouveau un prestigieux prix de gestion Eckert & Ziegler Isotopes Médecine Nucléaire Sociétés Les Mieux Gérées Deloitte Privé
BRIEF published on 05/23/2025 at 10:05, 1 year 5 months ago Eckert & Ziegler Receives Prestigious Management Award Again Eckert & Ziegler Nuclear Medicine Best Managed Companies Deloitte Private Isotopes
Published on 11/11/2026 at 03:30, 5 hours 34 minutes ago CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 8 hours 24 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 9 hours 34 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 10 hours 4 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 10 hours 4 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/11/2026 at 08:31, 33 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 500 million Convertible Bonds due 2029 (ISIN DE000A3MP437 – Common Code 238511097 – German Securities Code (WKN) A3MP43)
Published on 11/11/2026 at 08:30, 34 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 1,000 million Convertible Bonds due 2030 (ISIN DE000A30V5R1 – Common Code 258943848 – German Securities Code (WKN) A30V5R)
Published on 11/11/2026 at 08:30, 34 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 750 million Convertible Bonds due 2028 (ISIN DE000A3H2WQ0 – Common Code 220637387 – German Securities Code (WKN) A3H2WQ)
Published on 11/11/2026 at 08:30, 34 minutes ago aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%
Published on 11/10/2026 at 18:00, 15 hours 4 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 15 hours 19 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 15 hours 29 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 15 hours 33 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
